非功能化聚乙烯纳米颗粒与人体白蛋白和红细胞蛋白的相互作用:含义和潜在后果
Kamil Płuciennik1,2, Mariusz Szabelski3, Katarzyna Miłowska4
1Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90- 236, Lodz, Poland.
Scientific reports
|August 17, 2025
概括
非功能化聚烯纳米颗粒 (PS-NPs) 在体外改变人血清白蛋白 (HSA) 结构和红细胞蛋白. 影响取决于PS-NP的大小和度,可能导致与塑料有关的损害.
科学领域:
- 生物材料科学 生物材料科学
- 纳米毒理学研究
- 蛋白质化学 蛋白质化学
背景情况:
- 纳米粒子越来越多地用于各种应用,需要了解它们的生物相互作用.
- 聚乙烯纳米颗粒 (PS-NP) 在研究和工业中很常见,但它们对人类蛋白质的影响需要详细的研究.
- 人体血清白蛋白 (HSA) 和红细胞蛋白对生物功能至关重要,可能易受纳米粒子相互作用的影响.
研究的目的:
- 研究非功能化聚烯纳米颗粒 (PS-NP) 对人血清白蛋白 (HSA) 和人体红细胞蛋白的度和大小依赖的影响.
- 为了确定不同的尺寸 (~30 nm,~45 nm,~70 nm) 和PS-NP度在体外如何影响蛋白质结构和功能.
- 探索纳米粒子诱导蛋白质损伤的潜在机制及其对红细胞完整性的影响.
主要方法:
- 暴露HSA和人类红细胞在PS-NP的不同度 (0.001100μg/mL) 中24小时.
- 使用循环二极化 (CD),光谱和光寿命测量对HSA二次结构的分析.
- 评估红细胞的特性,包括相对粘度,蛋白质碳酸含量,乙胆化酶 (AChE) 活性和甲血球蛋白水平.
主要成果:
- 高度 (50100μg/mL) 的PS-NP显著改变了HSA二次结构,并增加了纳米粒子水力动力直径的所有测试大小.
- ~30nm和~45nmPS-NP诱导更强烈的HSA光和改变光寿命,表明直接相互作用.
- PS-NP (0.11μg/mL) 显著改变了红细胞的相对粘度和蛋白质碳酸含量增加,但没有影响ACHE活性或甲红球蛋白水平.
结论:
- 非功能化的PS-NP在体外显然影响人体血和红细胞蛋白的结构和功能性质.
- 观察到的效应取决于PS-NP的大小和度.
- 由PS-NPs诱导的HSA结构的改变可能间接导致体内与塑料有关的红细胞损伤.
相关概念视频
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
275
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
275
01:29Drug Distribution: Plasma Protein Binding
6.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.7K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
254
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
254
01:30Drug Binding to Blood Components
250
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
250
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
196
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
196
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114